Additional diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.
In the past decade significant advantages have been made in the treatment of rheumatoid arthritis (RA) and therapeutic strategies have changed a lot. These days, highly effective disease modifying anti-rheumatic drugs enable intervention early in the disease process, in order to prevent major joint damage. For years, serological support in the diagnosis of RA has been limited to the presence of rheumatoid factors, although not very specific for RA. During the last years a variety of circulating non-RF antibodies have been discovered and reported to be of potential diagnostic value. CCP2 proved to be a very disease-specific and even sensitive marker for RA. In addition to the diagnostic properties, CCP showed to be a good prognostic marker, CCP helps to predict the erosive or nonerosive progression of the disease, and CCP is already present early in the disease. This diagnostic tool enables the clinician to choose the optimal therapeutic management for each single RA patient.
Vallbracht
Inka
I
Krankenhaus München-Bogenhausen, Clinical Immunology/Rheumatology, Teaching Hospital of the University of Munich, Englschalkinger Str. 77, 81925 Munich, Germany. inka.vallbracht@extern.lrz-muenchen.de
Helmke
Klaus
K
D000906:Antibodies; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D010456:Peptides, Cyclic / Q000276:immunology*; D020033:Protein Isoforms; D012217:Rheumatoid Factor
D000906:Antibodies; D010456:Peptides, Cyclic; D020033:Protein Isoforms; C487763:cyclic citrullinated peptide; D012217:Rheumatoid Factor